Clinical EffectsThe effects of Firmagon were studied in a clinical trial in men with prostate cancer. In this study, some men were given Firmagon and some men were given leuprolide (Eligard®, Lupron®, Lupron Depot®), which is also a GnRH agonist. Both medications reduced testosterone levels to less than 50 nanograms (ng) per deciliter (dL) (a level considered clinically effective) in the majority of men over a 12-month period.
However, like other GnRH agonists, leuprolide caused an initial surge in testosterone levels. Only 18 percent of men given leuprolide had low testosterone levels after two weeks of treatment. In comparison, 96 percent of men receiving Firmagon had low testosterone levels within three days. This lack of testosterone surge is one of the advantages of Firmagon.
When and How to Use ItSome general considerations to keep in mind during treatment with Firmagon include the following:
- Firmagon is given as an injection just under the skin (subcutaneously) every four weeks (28 days).
- The injection is given under the skin of the abdomen (stomach). It is usually given by a healthcare provider in a healthcare setting, such as a doctor's office, hospital, or clinic.
- The exact site of the injection on your abdomen will change with each dose. The injection should not be given in an area that could be rubbed or pressed against, such as near the waistband, belt, or ribs.
- For this drug to work properly, it must be used as prescribed. Remember to schedule an appointment to receive your dose every four weeks.
Dosing InformationThere is only one standard dosage of this medication, regardless of your age or weight.
As is always the case, do not adjust your dose unless your healthcare provider specifically tells you to do so.
(Click Firmagon Dosage for more information.)